Celecoxib + Acetaminohen
Phase 3Small molecule
Celecoxib + Acetaminohen is one of 24 small molecule programs targeting Osteoarthritis. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
23
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
778 competitors in Osteoarthritis
#DrugCompanyPhaseTrials
1Celecoxib + Acetaminohen
LLaboratorios Silanes S.A. de C.V.
Phase 3
Toradol
RochePreclinical
Cataflam
NovartisPreclinical
Platelet Rich Plasma
ZZagazig University
Preclinical
Voltaren
CCerimon Pharmaceuticals
Preclinical
Enbrel
IImmunex
Preclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Protonix
WWyeth-Lederle Vaccines
Preclinical
Catapres
Boehringer IngelheimPreclinical
Paracetamol
GSKPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Celecoxib + Acetaminohen. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details